These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 387223)

  • 41. Cisplatin, vindesine, and bleomycin (DVB) combination chemotherapy for esophageal carcinoma.
    Kelsen DP; Bains M; Chapman R; Golbey R
    Cancer Treat Rep; 1981; 65(9-10):781-5. PubMed ID: 6168370
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy.
    Ostrow S; Egorin M; Aisner J; Bachur N; Wiernik PH
    Cancer Clin Trials; 1980; 3(1):23-7. PubMed ID: 7190082
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Etoposide and very high dose cisplatin: salvage therapy for patients with advanced germ cell neoplasms.
    Trump DL; Hortvet L
    Cancer Treat Rep; 1985 Mar; 69(3):259-61. PubMed ID: 2983893
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Corticosteroids and fluorouracil toxicity.
    Horton J; Olson KB; Hosley HF
    Arch Intern Med; 1966 Jun; 117(6):775-7. PubMed ID: 5327216
    [No Abstract]   [Full Text] [Related]  

  • 45. [Chemotherapeutic intolerance].
    Ellorhaoui M
    Z Gesamte Inn Med; 1976 Dec; 31(23):962-6. PubMed ID: 798432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Taxol: a promising new drug of the '90s.
    Rogers BB
    Oncol Nurs Forum; 1993; 20(10):1483-9. PubMed ID: 7904060
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of genitourinary tumours with cis-dichlorodiammineplatinum(II): experience in 250 patients.
    Merrin CE
    Cancer Treat Rep; 1979; 63(9-10):1579-84. PubMed ID: 574057
    [No Abstract]   [Full Text] [Related]  

  • 48. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
    Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
    Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Effects of cis-DDP in children with refractory malignant tumors].
    Nakadate H; Kobayashi R; Nishi M; Hatae Y; Takeda T; Uchino J; Hirama T; Kobayashi H
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):598-603. PubMed ID: 3954383
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I study of ICRF-187 using a daily for 3 days schedule.
    Von Hoff DD; Howser D; Lewis BJ; Holcenberg J; Weiss RB; Young RC
    Cancer Treat Rep; 1981; 65(3-4):249-52. PubMed ID: 6786738
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP).
    Rossof AH; Slayton RE; Perlia CP
    Cancer; 1972 Dec; 30(6):1451-6. PubMed ID: 4641756
    [No Abstract]   [Full Text] [Related]  

  • 52. Cisplatin, vindesine, mitomycin-C and 13-cis retinoic acid in the treatment of advanced non small cell lung cancer. A phase II pilot study.
    Recchia F; Sica G; De Filippis S; Rosselli M; Saggio G; Guerriero G; Pompili P; Rea S
    Anticancer Res; 2000; 20(3B):1985-90. PubMed ID: 10928138
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Phase II study of cis-diamminedichloroplatinum (II) in genitourinary cancer].
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):433-42. PubMed ID: 6764107
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II trail cisplatin in refractory childhood cancer: Children's Cancer Study Group Report.
    Baum ES; Gaynon P; Greenberg L; Krivit W; Hammond D
    Cancer Treat Rep; 1981; 65(9-10):815-22. PubMed ID: 6944156
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II trial of cisplatin in the treatment of patients with advanced or recurrent mixed mesodermal sarcomas of the uterus: a Gynecologic Oncology Group Study.
    Thigpen JT; Blessing JA; Orr JW; DiSaia PJ
    Cancer Treat Rep; 1986 Feb; 70(2):271-4. PubMed ID: 3948191
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Advanced ovarian carcinoma: a pilot study of cis-dichlorodiammineplatinum(II) in combination with adriamycin and cyclophosphamide in previously untreated patients and as a single agent in previously treated patients.
    Williams CJ; Stevenson KE; Buchanan RB; Whitehouse JM
    Cancer Treat Rep; 1979; 63(11-12):1745-53. PubMed ID: 393378
    [No Abstract]   [Full Text] [Related]  

  • 57. Comparative evaluation of two administration schedules of cis-dichlorodiammineplatinum (DDP) in ovarian and head and neck cancers: a CMEA chemotherapy group study.
    Mechl Z; Kerpel-Fronius S; Decker A; Gorbunova VA; Gürtler R; Hindy I; Krafft W; Kolarić K; Nekulova M; Sopkova B
    Neoplasma; 1987; 34(1):37-43. PubMed ID: 3561604
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical studies of Platinum Coordination compounds in the treatment of various malignant diseases.
    Hill JM; Loeb E; MacLellan A; Hill NO; Khan A; King JJ
    Cancer Chemother Rep; 1975; 59(3):647-59. PubMed ID: 1203889
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Nursing care in adverse effects of chemotherapy].
    Simonetti G
    Tijdschr Ziekenverpl; 1981 Jul; 34(15):644-50. PubMed ID: 6913266
    [No Abstract]   [Full Text] [Related]  

  • 60. Phase I clinical trial of combined therapy with 5-FU (NSC 19893) and CIS-platinum (II) diaminedichloride (NSC 119875).
    Ellerby RA; Davis HL; Ansfield FJ; Ramirez G
    Cancer; 1974 Oct; 34(4):1005-10. PubMed ID: 4607883
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.